O
Organon
A global healthcare company with a portfolio of therapies and products in women’s health
About Organon
Organon & Co. emerged as a standalone entity in June 2021, following a strategic spin-off from the pharmaceutical giant Merck & Co., known as MSD outside North America. This pivotal moment marked the beginning of a new chapter for Organon, positioning itself as a global leader in women's health, biosimilars, and established brands.
Originally, Organon was a Dutch pharmaceutical company with a rich history dating back to its founding in 1923. It was renowned for its contributions to reproductive medicine and contraception. Over the decades, Organon became a part of Merck & Co. through acquisition, which expanded its reach and capabilities.
The spin-off in 2021 was a significant event, allowing Organon to focus on its core mission of delivering impactful health solutions, particularly in women's health. This move was designed to unlock value for shareholders and provide Organon with the agility to pursue growth opportunities independently.
Since becoming independent, Organon has actively pursued acquisitions to bolster its portfolio, including companies like Dermavant, Forendo Pharma, and Alydia Health. These strategic moves have strengthened Organon's position in the healthcare sector, particularly in women's health and dermatology.
Today, Organon is headquartered in the United States and trades on the New York Stock Exchange under the ticker symbol OGN. The company's journey from a historic Dutch pharmaceutical firm to a modern, independent leader in women's health underscores its commitment to innovation and improving health outcomes globally.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2021
- Headquarters
- Jersey City, United States
- Listing
- IPO 2021
- Employees
- 6,938
- Open positions
- 94
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Biotechnology, Femtech, Woman Founder, Horizon Europe
- Business model
- Manufacturing
- Client focus
- b2b, b2c
- Investment activity
- 3 companies, latest Sep 2024
- Capital deployed
- $0
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2026 | $12B | $12B | Sun Pharmaceutical Industries | ↗ |
| POST IPO EQUITY✓Other financing | Mar 2026 | $0 | — | sio capital management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Organon is 160K monthly website visits, down 5.9% over the last three months. Organon's team declined 5.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Dermavant SciencesLong Beach, United StatesTreatments in Medical Dermatology. Subsidiary of Roivant
→
Claria MedicalMountain View, United StatesMinimally invasive surgical instruments for gynecologic procedures
→
Forendo PharmaTurku, FinlandClinical stage drug development company focused on novel therapeutic solutions for women's health
$75Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
sio capital management
Other known investors2 additional known investors
Sun Pharmaceutical Industries
Pivot Park
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Organon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Organon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.